Interest in antibodies to insulin developed with the genesis of the first reaction at the site of insulin injection (1) (2) (3) . It was almost inevitable that once the existence of antibodies to insulin had been suggested, the effect of these on the insulin itself would be questioned. Studies performed on the serum of insulin resistant patients provided further impetus to the concept that antibodies to insulin inhibit the action of insulin, thus necessitating the use of of higher doses than would otherwise have been the case (1, (4) (5) (6) (7) (8) (9) (10) (11) (12) (13) (14) (15) (16) (17) . In some instances the methods then available could demonstrate antibodies to insulin by direct skin testing, by passive transfer, by complement fixation or by the use of collodion particles (2, 3, 18, 19) . It was learned that skin sensitizing antibodies were present only in patients who had allergic reactions to insulin and were independent of the patient's insulin requirements (3-7, 18, 20) . This appeared to indicate that if an antibody were present in the insulin resistant patient, this antibody was distinct from the skin sensitizing antibody. In most cases, this suspected antibody did not precipitate insulin, fix complement, hemolyze red cells or do anything else easily recognized. Therefore, the presence of this antibody had to be determined by neutralization or reduction of the physiological action of insulin.
The following experimental approaches have been used:
1. Treatment of insulin resistant patients with human insulin (6, 20 (8, 9, 13, 15, 16, 20, 27 ). 7 . Studies of the effect of selected plasma and added insulin on the blood sugar of animals (8, 9, 11, 12, 16, 27) .
As a result of these various experiments, it is apparent that the inhibition of insulin may occur through several different mechanisms, all of which are by no means clearly understood. These mechanisms are of three general types: a) cellular, i.e., by competition with or antagonism of the cellular function of insulin; b) enzymatic destruction of insulin; and c) binding of insulin to circulating protein.
Since an enzyme is a protein which has a definite affinity for its substrate, insulinase might be considered an antibody if it occurred as a response to the injection of insulin. However, this response has never been demonstrated clearly and indeed insulinase activity has been found in sera of patients and animals that have never received insulin (27, 28) . It is the third type of inhibition which is most clearly due to an antibody and is the subject of this study. The binding of insulin by serum has been demonstrated only in patients and animals that have received injections of heterogenous insulin. Indeed, it is a regular response to such injections (29, 30) . 787
In the preceding paper (31), a method was presented for demonstrating the binding of insulin by the gamma globulins in any given serum. Using this method the insulin binding by the serum of 48 patients was determined. The term "insulin binding" is used to designate the percentage of insulin which is bound by the gamma globulins of an individual serum under standardized conditions (31) . Each serum was analyzed within 48 hours after it was obtained and then frozen at -20 C. Since the concentrations of insulin in different lots of I' insulin may vary somewhat, all of the results presented here were obtained from a simultaneous reanalysis of all the sera. The final and initial analyses did not differ in any case by more than 10 per cent. If less than 1 per cent of the radioactive insulin was bound by a 1: 25 dilution of the individual serum, then this serum was classified in this paper as negative. Otherwise the actual per cent of insulin bound is given. Since the percentage binding is a result of both the amount of antibody present and the equilibrium constant of the antigen-antibody reaction, the results should not be interpreted as indication of the absolute amount of antibody present. However, due to the relatively slow turnover of globulins in humans, any sudden change in binding should reflect a similar change in the concentration of antibody. The amount of I' insulin added under the conditions of the test is equivalent to 66 units per liter of undiluted serum. Since the amount of unlabeled insulin contained in the serum will, under almost any conceivable condition, be small in comparison to the labeled insulin added, and since the Table II presents similar data for patients whose insulin has been discontinued, with or without reinstitution of insulin. It may be seen that in some patients the antibodies persist as long as three years after treatment has 'been stopped. However, the average insulin binding of the sera in this group is lower than in the group currently receiving insulin (Table I) .
In two patients (P. S. and G. S.), a rise in insulin binding with duration of insulin treatment was observed despite a reduction in the insulin dosage. No differences could be demonstrated at different times of the day although blood sugar levels (and presumably exogenous insulin concentration) vary 3. Antibodies were demonstrable in two patients who had received no insulin for three years.
4. An increase in insulin binding of a patient's serum was never found to precede or immediately follow an increase in insulin requirement or dosage.
5. No consistent relationship could be demonstrated between the insulin binding and the insulin requirements of patients receiving insulin.
On the basis of the evidence presented in this and the preceding paper, it would appear that the insulin binding demonstrated by precipitation with antihuman gamma globulin is due to the same antibodies which have been demonstrated electrophoretically (13, 29) . The finding that the binding of insulin could be demonstrated only in the sera of patients treated with insulin strengthens the conclusion of Berson, Yalow, Bauman, Rothschild, and Newerly (29) that the globulin responsible for this binding should be considered an antibody. It does not necessarily follow, however, that the affinity of insulin for the antibody is unchanged by the I131 label.
The lack of relationship between insulin binding and the insulin requirements of the p1atient is in apparent contradiction to the recent reports of Berson and Yalow (30, 33) and Burrows, Peters, and Lowell (34) that the sera of insulin resistant patients show much greater binding of insulin than do the sera of nonresistant patients. These authors found that the sera of insulin resistant patients bound 80 to 800 units of insulin per liter of serum, whereas nonresistant patients' sera rarely bound more than 10 units. Under the conditions of the present study (31) , 100 per cent binding A partial explanation of the relative lack of effect of insulin antibody on the insulin requirements of the diabetic patient has been given by Yalow and Berson (35) in the inhibition of liver insulinase activity by serum containing insulin binding antibody. In contrast to the effect of antibody in accelerating antigen breakdown in some systems (36) , the insulin antibody appears to retard antigen metabolism (29) . Just as the binding of insulin in a protamine precipitate does not increase total insulin requirement, the binding by antibody will not increase total insulin requirement if 1) the breakdown of the insulin is not accelerated, and 2) if either of the following obtains: a) the insulin-antibody bond is reversible, or b) the insulin-antibody complex is physiologically active. No information is available concerning the activity of the insulin-antibody complex, but evidence for the reversibility of the insulinantibody bond has been given by Berson and Yalow (29) and by Skom and Talmage (31) . Therefore, the two most apparent explanations for the relative lack of effect of antibodies on the insulin requirements of the patient are: 1) the failure of insulin antibodies to accelerate the metabolism of insulin, and 2) the reversibility of the insulin-antibody bond. As the free insulin is utilized by the cells and the free insulin concentration falls, the complex dissociates more rapidly than it forms, yielding more free insulin. As long as the binding of insulin is only temporary and does not lead to its accelerated metabolism, no increase in insulin requirements will result.
In contrast to the relative ineffectiveness of binding antibody in increasing the long term insulin requirement of the patient, binding antibody would be expected to increase the dose of insulin required for a given immediate effect. An example of this may be the increasing dosage of insulin required to induce shock in a schizophrenic patient receiving repeated injections. Berson and Yalow (30) suggest that the total effect of the insulin is not reduced by the presence of antibody in such cases but only delayed so that the hypoglycemia may be more prolonged. SUMMARY 1. The insulin binding of the sera of 48 subjects has been determined.
2. Insulin binding was demonstrated in the sera-of all 23 patients who had received insulin recently for more than one month.
3. Twelve control sera from patients who had never received insulin were all negative.
4. No consistent relationship could be demonstrated between the insulin binding and the insulin requirements of patients receiving insulin. The explanation of this relative lack of effect of insulin binding antibodies has been discussed.
